Arbutus Biopharma (ABUS) Interest & Investment Income (2013 - 2026)

Arbutus Biopharma has disclosed Interest & Investment Income across 14 years of filings, most recently posting $815000.0 for Q1 2026.

• Interest & Investment Income for Q1 2026 came in at $815000.0, down 31.91% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.7 million (down 40.9% YoY), and the FY2025 annual result was $4.1 million, down 38.22% from the prior year.
• Interest & Investment Income came in at $815000.0 for Q1 2026 at Arbutus Biopharma, down from $877000.0 in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $1.8 million in Q2 2024 to a low of $159000.0 in Q1 2022.
• The 5-year median for Interest & Investment Income is $1.2 million (2025), against an average of $1.1 million.
• Across the five-year window, Interest & Investment Income surged 3043.33% in 2022 and slumped 45.51% in 2025, its largest moves.
• Arbutus Biopharma's Interest & Investment Income stood at $943000.0 in 2022, then jumped by 55.36% to $1.5 million in 2023, then declined by 0.07% to $1.5 million in 2024, then slumped by 40.1% to $877000.0 in 2025, then retreated by 7.07% to $815000.0 in 2026.
• The last three Interest & Investment Income figures came in at $815000.0 (Q1 2026), $877000.0 (Q4 2025), and $952000.0 (Q3 2025), per Business Quant data.